RT Journal Article
SR Electronic
T1 Enoxaparin Strategy Appears to Reduce Reinfarction Better than Commonly Administered Unfractionated Heparin in ST Elevation Myocardial Infarction
JF MD Conference Express
YR 2006
FD SAGE Publications
VO 6
IS 1
SP 20
OP 20
DO 10.1177/155989770601009
UL http://mdc.sagepub.com/content/6/1/20.abstract
AB Treatment with enoxaparin (a low molecular weight heparin) throughout hospitalization (up to 8 days) significantly reduced the risk of death or nonfatal reinfarction, compared to administration of unfractionated heparin (UFH) for 48 hours in patients with ST-elevation myocardial infarction (STEMI) undergoing fibrinolytic therapy, according to findings from the multicenter multinational ExTRACT-TIMI 25 trial lead by the investigators from the Brigham and Women's Hospital.